Robert Reiter, MD Robert Reiter, MD

About Dr. Reiter

Dr. Robert Reiter is a Professor of Urology and Molecular Biology, Director of the Prostate Cancer Treatment and Research Program, and Director of Urologic Research at the Geffen School of Medicine at UCLA.  Dr. Reiter has been a full time faculty member at UCLA since 1995. He completed his undergraduate studies at Yale University and then went on to study medicine at Stanford University Medical School. He completed residency training in general surgery at Stanford. He completed his urologic training at Baylor College of Medicine (in Houston), one of the foremost programs in urology in the United States. At Baylor, he studied under Dr. Peter Scardino, one of the world's preeminent prostate cancer surgeons. Dr. Reiter completed additional fellowship training in urological cancer (eg.prostate, kidney, bladder and testicular cancer) at the National Cancer Institute. Dr. Reiter also completed three years of postdoctoral laboratory training focused on molecular biology of prostate and kidney cancer while at the NCI and subsequently at UCLA.

At UCLA, Dr. Reiter specializes in the treatment of prostate cancer, offering expertise in management of all stages of the disease, with special emphasis on robotic prostatectomy. He also has more than a decade of experience in open radical prostatectomy and brachytherapy (radioactive seeds). Dr. Reiter also has special expertise in the management of bladder and kidney cancer, and benign prostate enlargement. He was one of the first practitioners of greenlight laser prostatectomy for enlarged prostates and has been involved in multiple clinical studies of this treatment modality. Dr. Reiter offers robotic cystectomy for bladder cancer (together with continent urinary diversion) and robotic partial nephrectomy for patients with kidney cancer. In addition to expertise in the surgical management of localized prostate cancer, Dr. Reiter also offers innovative treatments for high risk and advanced prostate cancer, including the latest clinical trials and systemic targeted therapies.  His group has led the integration of MRI imaging into the management of men with localized and high-risk prostate cancer.

In addition to his clinical practice, Dr. Reiter runs a large basic and applied research program in prostate cancer. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar multifaceted research program that strives to translate basic science advances in prostate cancer to the management of men with this disease. There are currently only 9 active SPORE programs in the United States, of which UCLA’s is the only such program in California. In addition, Dr. Reiter is only one of two urologists who lead such programs in the country. Dr. Reiter’s own research focuses on four main areas: (1) the development of antibodies against prostate cancer proteins that can be used to treat prostate cancer (2) novel imaging technologies for prostate cancer, including radiolabeled antibodies for PET imaging and MRI for local cancer imaging (3) the application of molecular markers to predict prostate cancer prognosis and for the personalization of therapy, and (4) the role of stem cells in prostate cancer. Dr. Reiter’s lab has gained international attention for its discovery of the PSCA (prostate stem cell antigen) gene and the development of antibodies against PSCA that have entered clinical trials for both the treatment and imaging of prostate (as well as pancreatic) cancer. His lab was among the first to discover the utility of the molecular marker p27 as a prognostic factor in prostate cancer.

In addition to the SPORE grant, Dr. Reiter has won numerous awards and honors, including the Stop Cancer Young Investigator Award, the Society for Urologic Oncology Young Investigator Award, and election to the American Society for Clinical Investigation. His work has been funded continuously for 14 years by the National Cancer Institute, the American Cancer Society, the Department of Defense, the New York Academy of Medicine, the Margaret Early Trust and other funding agencies. 

Dr. Reiter is married and has three young children. He loves to travel, ski, play tennis, and spend time with family and friends.

Not logged in | Log In